Fosun Pitches For India’s Gland
This article was originally published in PharmAsia News
China’s Shanghai Fosun Pharma has confirmed its interest in the Indian injectables firm Gland Pharma, underscoring how differentiated niche plays continue to attract buyer interest.
You may also be interested in...
Fosun Pharma, Shanghai Pharma Deny Interest In Stada
Fosun Pharma and Shanghai Pharma have both officially denied their involvement in any bidding battle for German company Stada, although both Chinese firms make no secret of their international expansion ambitions and have been active deal makers in the past.
Chinese Stamp On Indian Pharma; All Eyes On Regulatory Flow
The Fosun group led by its billionaire chair Guo Guangchang has snapped up the injectables firm Gland for around $1.26bn, the first mega Chinese buy in the Indian pharmaceutical space. The deal opens up many potential collaborative opportunities, though it remains to be seen how smoothly it sails through in the Indian regulatory maze.
First Cetuximab Biosimilar Debuts In India; Merck KGaA Sticks To Guns
Alkem’s ‘affordable’ cetuximab biosimilar set to take on Erbitux in India, even as Merck KGaA pursues a court case seeking information and data related to efficacy and interchangeability of the Indian company's product.